Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
The history of sodium-glucose cotransporter 2 inhibitors (SGLT2i) is so long and started in 1835 when Petersen extracted a compound called phlorizin from apple tree bark. About fifty years later, von Mering discovered its glucosuric properties. In the 1980s, it was discovered that the glucosuria res...
Saved in:
| Main Authors: | Angelica Cersosimo, Andrea Drera, Marianna Adamo, Marco Metra, Enrico Vizzardi |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-10-01
|
| Series: | Kidney and Dialysis |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-8236/4/4/16 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
by: Dana Darwish, et al.
Published: (2025-06-01) -
Double Duty: SGLT2 Inhibitors as Cardioprotective and Anticancer Allies
by: Linda Piras, et al.
Published: (2024-11-01) -
Cardiac Fibrosis: Mechanistic Discoveries Linked to SGLT2 Inhibitors
by: Filip Rolski, et al.
Published: (2025-02-01) -
SGLT2 inhibitors in preventing progression of chronic kidney disease in patients with type 2 diabetes: a literature review
by: Michał Szczepański, et al.
Published: (2024-12-01) -
Early administration of SGLT2 inhibitors in hospitalized patients: A practical guidance from the current evidence
by: Ruggero Mazzotta, et al.
Published: (2025-08-01)